94 related articles for article (PubMed ID: 12187809)
1. [A case of multiple myeloma with infiltration into skeletal muscle after injections of a granulocyte-colony stimulating-factor].
Kikuchi M; Inagaki T; Ueda R
Nihon Ronen Igakkai Zasshi; 2002 Jul; 39(4):433-8. PubMed ID: 12187809
[TBL] [Abstract][Full Text] [Related]
2. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
Raina V; Sharma A; Kumar R; Bhargava M
Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
[TBL] [Abstract][Full Text] [Related]
3. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
4. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
6. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
[TBL] [Abstract][Full Text] [Related]
7. [Granulocyte-colony stimulating factor-producing myeloma with clinical manifestations mimicking chronic neutrophilic leukemia].
Kusaba N; Yoshida H; Ohkubo F; Mishima K; Shimamastu K; Okamura T; Sata M
Rinsho Ketsueki; 2004 Mar; 45(3):228-32. PubMed ID: 15103937
[TBL] [Abstract][Full Text] [Related]
8. Massive extramedullary disease progression in a patient with stable multiple myeloma during G-CSF priming for peripheral blood progenitor mobilization.
Kobbe G; Germing U; Soehngen D; Aul C; Heyll A
Oncol Rep; 1999; 6(5):1151-2. PubMed ID: 10425318
[TBL] [Abstract][Full Text] [Related]
9. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
10. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
[TBL] [Abstract][Full Text] [Related]
11. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
13. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Stahel RA; Jost LM; Honegger H; Betts E; Goebel ME; Nagler A
J Clin Oncol; 1997 May; 15(5):1730-5. PubMed ID: 9164179
[TBL] [Abstract][Full Text] [Related]
15. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
Musto P; Scalzulli PR; Terruzzi E; Rossini F; Iacopino P; Messina G; Guariglia R; Pietrantuono G; Villani O; D'Auria F; Falcone A; Sanpaolo G; Valvano MR; Pogliani EM; Morabito F
Leuk Res; 2007 Nov; 31(11):1487-93. PubMed ID: 17320951
[TBL] [Abstract][Full Text] [Related]
16. [A case of aggressive multiple myeloma].
Oda Y; Ooi S; Endoh A; Urushidani Y; Nakamura R; Adachi K
Gan To Kagaku Ryoho; 2011 Mar; 38(3):489-92. PubMed ID: 21403462
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
18. [Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF)].
Kanbayashi Y; Mukoyama N; Nishida K; Shimizu D; Matsumoto Y; Nomura K; Horiike S; Taniwaki M
Gan To Kagaku Ryoho; 2006 Jan; 33(1):73-7. PubMed ID: 16410701
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
[TBL] [Abstract][Full Text] [Related]
20. Rapid progression of multiple myeloma following G-CSF mobilization.
de la Rubia J; Bonanad S; Palau J; Sanz GF; Sanz MA
Bone Marrow Transplant; 1994 Sep; 14(3):475-6. PubMed ID: 7527691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
